Switch View
© PR Newswire
17.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for Worldwide Healthcare Trust PLC at the close of business on 16 September 2025 was 348.48p (cum income). For and on behalf of the B...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /CNW/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on y...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic to...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Advancing Cancer Research Brings New Hope for Patients Worldwide
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic to...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
17.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
News Preview
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies
Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study
Robust findings continue...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US29405E2081
Enveric Biosciences, Inc.
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
News Preview
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US5747951003
Masimo Corporation
MASI
LISTED
NASDAQ
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs
News Preview
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1
This press release...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: DK0060055861
Chemometec A/S
CHEMM
LISTED
CPH
Notice of Annual General Meeting 2025
News Preview
ANNOUNCEMENT NO. 293...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
News Preview
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss...
Themefolio
Profiler
Peergroup
© Newsfile
17.09.2025
ISIN: CA9255401064
Vext Science, Inc.
VEXT
LISTED
CSE
Vext Secures State Approval for Portsmouth Dispensary Ownership Transfer
News Preview
Upon closing, expected by October 1, 2025, Portsmouth will become Vext's fifth fully consolidated dispensary in Ohio. The Company expects to bring additional locations online through late 2025 and early 2026, progressing toward the state's eight-store cap.Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Vext Science, Inc. (CSE:...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: BE0003739530
UCB SA
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
News Preview
High responses maintained over four years in nearly half of patients: 48.9% of Week 16 PASI 0 responders sustained complete skin clearance of psoriasis, achieving PASI 0 at every study visit, from Week 16 to four years*Nail psoriasis improvements: 81.8% and 82.7% of patients achieved nail matrix and nail bed mNAPSI 0, respectively, resolution of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
17.09.2025
ISIN: BE0003739530
UCB SA
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
News Preview
Symptom relief sustained to three years: Improvements in the stringent endpoints HiSCR75, HiSCR90, and HiSCR100 at one year were sustained to three years in 81.2%, 64.3%, and 50.1% of patients, respectively*Resolution of inflammatory lesions: Of patients who achieved IHS4-100 (European clinical metric to assess the severity of HS1) at year one, 6...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US98419J2069
XOMA Royalty Corp
XOMA
LISTED
NASDAQ
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
News Preview
XOMA Royalty closes tender offer for HilleVax....
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Appoints Tom Stewart as Chief Financial Officer
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced that Tom Stewart has been appointed Chief Financial Officer, effective immediately.
Mr. Stewart’s appointment supports the continued execution of...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US74587B1017
Pulse Biosciences Inc
PLSE
LISTED
NASDAQ
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Com...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on November 3, 2025, to stockholders of record at the close of business on October 3, 2025.
In addition, the Board of Direc...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US69608A1088
Palantir Technologies, Inc.
PLTR
LISTED
NASDAQ
Palantir Technologies Achieves Cybersecurity Maturity Model Certification (CMMC) Level 2
News Preview
Palantir Technologies Inc. (NASDAQ: PLTR), today announced it has achieved Cybersecurity Maturity Model Certification (CMMC) Level 2 through an assessment by a CMMC Third-Party Assessment Organization (C3PAO). CMMC Certification through C3PAO assessment reinforces Palantir's commitment to securing national defense data and supporting critical gove...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics
News Preview
FRANKLIN LAKES, N.J., Sept. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1,000th BD Rhapsody™ System, a flagship instrument for single-cell multiomics analysis, at Addenbrooke's Hospital of the University of Cambridge, United Kingdom. Together...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US64131A1051
Neuronetics Inc
STIM
LISTED
NASDAQ
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
News Preview
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US20678X1063
Conduit Pharmaceuticals Inc.
CDT
LISTED
NASDAQ
CDT Executes Cryptocurrency Treasury Reserve Strategy
News Preview
CDT Executes Cryptocurrency Treasury Reserve Strategy...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US92859E1082
Vivos Therapeutics Inc.
VVOS
LISTED
NASDAQ
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
News Preview
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US92854B1098
Vivani Medical, Inc.
VANI
LISTED
NASDAQ
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
News Preview
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US1140822099
Eterna Therapeutics Inc.
ERNA
LISTED
NASDAQ
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
News Preview
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microe...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
News Preview
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Socie...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US1717571079
Cidara Therapeutics, Inc.
CDTX
LISTED
NASDAQ
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
News Preview
- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US28657F1030
Elicio Therapeutics, Inc.
ELTX
LISTED
NASDAQ
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
News Preview
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced immunogenicity testing data showing that approximately 99% of evaluable patients (89 of 90) enrolled in i...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US0167441049
Allarity Therapeutics, Inc.
ALLR
LISTED
NASDAQ
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
News Preview
Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
News Preview
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were h...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US00887A2042
Rein Therapeutics Inc
ALRN
LISTED
NASDAQ
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
News Preview
Peer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US00534A1025
Invivyd Inc
IVVD
LISTED
NASDAQ
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
News Preview
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
News Preview
Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US82657M1053
Sight Sciences Inc
SGHT
LISTED
NASDAQ
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
News Preview
The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucoma The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that f...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US5288723027
Lexicon Pharmaceuticals Inc
LXRX
LISTED
NASDAQ
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
News Preview
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
News Preview
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US98420X2027
X4 Pharmaceuticals Inc
XFOR
LISTED
NASDAQ
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
News Preview
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US89854M1018
TScan Therapeutics, Inc.
TCRX
LISTED
NASDAQ
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
News Preview
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: BMG762791017
Roivant Sciences Ltd
ROIV
LISTED
NASDAQ
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
News Preview
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM)....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
News Preview
Denifanstat met all primary and secondary endpoints versus placebo...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US8902604094
Tonix Pharmaceuticals Holding Corp.
TNXP
LISTED
NASDAQ
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
News Preview
Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US5015751044
Kymera Therapeutics Inc
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
News Preview
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US14843C1053
Castle Biosciences Inc
CSTL
LISTED
NASDAQ
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
News Preview
Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek....
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: KR7196170005
Alteogen Inc
196170
LISTED
KOE
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)
News Preview
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical.DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name:...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US15117B1035
Celldex Therapeutics, Inc.
CLDX
LISTED
NASDAQ
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
News Preview
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
ISIN: US7389201077
Aspire Biopharma Holdings, Inc
ASBP
LISTED
NASDAQ
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
News Preview
BUZZ BOMB™ engages three specialized fitness influencers to grow the brandhttps://www.instagram.com/bobbymaximus/https://www.instagram.com/midwest_kong/https://www.instagram.com/ifbbpro_moose_the_stallion/The influencers have hundreds of thousands of followers across social platformsBUZZ BOMB's™ influencers known for their authenticity...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: SE0014855029
Implantica AG
IMP A-SDB
LISTED
STO
Implantica's RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval
News Preview
VADUZ, Liechtenstein, Sept. 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces RefluxStop® was met with great enthusiasm and posi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
News Preview
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD studyPreclinical proof-of-concept d...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US03969K1088
Arcutis Biotherapeutics Inc
ARQT
LISTED
NASDAQ
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
News Preview
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: DK0060027142
ALK-Abelló A/S
ALK B
LISTED
CPH
ALK and GenSci partner to expand the AIT market in China
News Preview
Inside Information...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: FR0012634822
Maat Pharma S.A.
MAAT
LISTED
EURONEXT
MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update
News Preview
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced its half year financial results for the six-month period ended June 30,...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Reports First Half 2025 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2025. The consolidated financial statements are attached to this press release.
“With key milestones anticipated over the next 12 months, our primary focus will be...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
News Preview
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support th...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: CH1335392721
Galderma Group AG
GALD
LISTED
XWSX
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
News Preview
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (G...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
News Preview
Pressemitteilung // 17. September 2025
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
Planegg-Martinsried – Die Formycon AG (FWB: FYB, „Formycon“) gibt bekannt, dass die Klinge Biopharma GmbH („Klinge“), Lizenznehmer und exklusiver Inhaber der weltwe......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
News Preview
Press Release // September 17, 2025
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global co......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US6876041087
Oruka Therapeutics, Inc.
ORKA
LISTED
NASDAQ
Oruka Therapeutics Announces $180 Million Private Placement
News Preview
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
News Preview
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US6876041087
Oruka Therapeutics, Inc.
ORKA
LISTED
NASDAQ
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
News Preview
Half-life of approximately 100 days increases likelihood of once-per-year dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified instit...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
